At Ironshore Pharmaceuticals & Development, Inc. we use proprietary drug-delivery technology to develop improved versions of existing drug products.
Ironshore Pharmaceuticals & Development, Inc. is a biopharmaceutical company whose mission is to develop innovative, patient-centric treatment options, utilizing its proprietary DELEXIS® technology, to improve the lives of patients and caregivers. Based in Grand Cayman, Ironshore is responsible for managing all intellectual property, and directing all research, development and manufacturing activities for its drug candidates. Ironshore is a wholly owned subsidiary of Toronto-based Highland Therapeutics Inc.
Ironshore's lead compound, HLD200 (delayed-release and extended-release methylphenidate) is under development for the treatment of Attention-Deficit/Hyperactivity Disorder, or ADHD. A New Drug Application has been submitted to the U.S. Food and Drug Administration.
Research & Development Headquarters
10 Market Street
Camana Bay, KY1-9006
MaRS Centre, South Tower
101 College St, Suite 200
Toronto, ON Canada M5G 1L7